Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment

Journal of Affective Disorders

Volumn 68, Issue 2-3, 2002, Pages 243-249

  Brunswick, David J ^a   Amsterdam, Jay D ^a   Fawcett, Jan ^b   Quitkin, Frederic M ^c   Reimherr, Frederick W ^d   Rosenbaum, Jerrold F ^e   Beasley Jr , Charles M ^f  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; NORFLUOXETINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOXETINE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 0036286762     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(00)00333-5     Document Type: Article

References (26)

1. The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels
2. Fluoxetine and norfluoxetine plasma concentrations in major depression: A multicenter study
3. Tricyclic antidepressants-blood level measurements and clinical outcome: Task force on the use of laboratory tests in psychiatry
4. Fluoxetine: Relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression
5. Fluoxetine: Relationships among plasma concentrations and therapeutic effects in the treatment of 32 patients with major depressive disorder at 20 mg/day
6. What constitutes an "adequate" duration of antidepressant treatment?
7. Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing
8. Sertraline in the prevention of depression
9. Long-term treatment of major depressive disorder with paroxetine
10. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo
11. A rating scale for depression
12. Identifying sources of outcome variability in clinical drug trials
13. Serum fluoxetine and norfluoxetine concentrations and antidepressant response
14. Imipramine and amitriptyline plasma concentrations and clinical response in major depression
15. Relationship between parameters of serotonin transport and antidepressant plasma-levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline
16. Plasma-level response relationships with fluoxetine and zimelidine
17. The prophylactic efficacy of fluoxetine in unipolar depression
18. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
19. Determination of fluoxetine and norfluoxetine in plasma by gas chromatography with electron-capture detection
20. Early non-response to fluoxetine as a predictor of poor 8-week outcome
21. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine
22. Tricyclic antidepressant concentrations in plasma: An estimate of their sensitivity and specificity as a predictor of response
23. Optimal length of continuation therapy in depression: A prospective assessment during long-term fluoxetine treatment
24. Paroxetine plasma levels: Lack of correlation with efficacy or adverse events
25. The relationship between response to fluoxetine, plasma drug levels, imipramine binding to platelet membranes and whole-blood 5-HT
26. Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors